PHAT
Phathom Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$12.58
+0.17 (+1.37%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 68.48M | 173.93M | 162.51M | 174.28M |
| Net Income | -414,335,962 | 52.15M | 46.06M | 49.26M |
| EPS | — | — | — | — |
| Profit Margin | -605.1% | 30.0% | 28.4% | 28.3% |
| Rev Growth | — | -4.6% | -5.1% | +14.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 272.85M | 290.01M | 278.72M | 245.03M |
| Total Equity | 219.62M | 430.20M | 411.26M | 463.12M |
| D/E Ratio | 1.24 | 0.67 | 0.68 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -342,891,977 | 99.13M | 88.44M | 98.15M |
| Free Cash Flow | — | 45.89M | 35.44M | 36.11M |